ArticleBMC dermatology2003
Psoriasin (S100A7) expression is altered during skin tumorigenesis.
Article in BMC dermatology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Pooled it
- Antimicrobial Peptides of the Skin: Roles in Skin Cancer and Clinical Applications.Experimental dermatology · 2026Review
- Biomarkers in Cutaneous Keratinocyte Carcinomas.Dermatology and therapy · 2024Review
- GLI Transcriptional Targets S100A7 and KRT16 Show Upregulated Expression Patterns in Epidermis Overlying the Tumor Mass in Melanoma Samples.International journal of molecular sciences · 2024Article
- Anoikis-related gene signatures predict prognosis of lung adenocarcinoma patients and reveal immune infiltration.Translational cancer research · 2024Article
- Pathogenic role of S100 proteins in psoriasis.Frontiers in immunology · 2023Review
- Psoriasin expression is associated with survival in patients with human papillomavirus-positive base of tongue squamous cell carcinoma.Oncology letters · 2021Article
- Role of oncostatin M in the pathogenesis of vernal keratoconjunctivitis: focus on tissue remodeling.Japanese journal of ophthalmology · 2021Article
- Differential expression and role of S100 proteins in chronic rhinosinusitis.Current opinion in allergy and clinical immunology · 2020Review
- Differences in gene expression between high-grade dysplasia and invasive HPVCancer medicine · 2019Article
- Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment.Breast cancer research : BCR · 2017Article
- Molecular and cellular impact of Psoriasin (S100A7) on the healing of human wounds.Experimental and therapeutic medicine · 2017Article
- Human S100A7 Induces Mature Interleukin1α Expression by RAGE-p38 MAPK-Calpain1 Pathway in Psoriasis.PloS one · 2017Article
- Article
- The role of antimicrobial peptides in chronic inflammatory skin diseases.Postepy dermatologii i alergologii · 2016Review
- The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma.PloS one · 2016Article
- Psoriasin (S100A7) is a novel biomarker for lung squamous cell carcinoma in humans.Cancer cell international · 2015Article
- Article
- Knockdown of S100A7 reduces lung squamous cell carcinoma cell growth in vitro and in vivo.International journal of clinical and experimental pathology · 2014Article
- Overexpression of S100A7 protects LPS-induced mitochondrial dysfunction and stimulates IL-6 and IL-8 in HaCaT cells.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriasin (S100A7) expression has previously been associated with psoriasiform hyperplasia as well as with tumor progression in breast cancer. Its expression profile for different stages of skin lesions is unknown. The aim of this study was to determine the relationship between psoriasin (S100A7) and tumor progression in skin.
methodsPsoriasin was assessed by immunohistochemistry and levels of expression determined by semi-quantitative scoring in skin biopsies from 50 patients. The cohort included normal skin, actinic keratosis, squamous carcinoma in-situ, invasive squamous cell carcinoma, and basal cell carcinoma.
resultsIn normal skin, psoriasin was rarely detected in epidermis but was expressed in underlying adnexae. In abnormal epidermis psoriasin was frequently expressed in abnormal keratinocytes in actinic keratosis, in-situ and invasive squamous cell carcinoma, but was rarely observed in the basal epidermal layer or in superficial or invasive basal cell carcinoma. The highest levels of expression were seen within squamous carcinoma in-situ. Significantly reduced levels of expression were observed in both unmatched (p = 0.0001) and matched (p < 0.004) invasive squamous cell carcinoma. Psoriasin expression within abnormal squamous lesions correlated with mitotic count (r = 0.54, p = 0.0036), however no significant relation was found with the intensity of dermal inflammatory cell infiltrates assessed within each pathology.
conclusionThese results suggest that altered psoriasin expression occurs in abnormal epidermis and that downregulation may be related to the onset of invasion in squamous cell carcinoma in skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.